Pfizer Inc.
Pharmaceutical company, collaboration partner on Padcev
Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →
Key metrics · each point sourced
Stated objectives
Enhance global ADC access through acquisition of Seagen
sourceObtain regulatory approval for HYMPAVZI for treatment of hemophilia A or B with inhibitors from FDA and EMA
sourceComplete BASIS KIDS study to evaluate safety and efficacy of HYMPAVZI in children up to <18 years with hemophilia A or B with or without inhibitors
sourceEvaluate long-term safety and efficacy of HYMPAVZI in hemophilia patients with or without inhibitors in ongoing open-label long-term extension study
sourceAchieve revenues between $59.5 billion and $62.5 billion in 2026
sourceAchieve adjusted EPS between $2.80 and $3 per share in 2026
sourceEstablish BRAFTOVI as standard of care for BRAF V600E-mutant metastatic colorectal cancer
sourcePfizer 2026 revenue guidance midpoint
sourcePfizer 2026 EPS guidance midpoint
sourceExpand HYMPAVZI indication to include hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients ages 6 to 11 without inhibitors
source